Linagliptin: The Game Changer in Type 2 Diabetes Mellitus

The rate of occurring of Type 2 diabetes mellitus have been proportionally increased with respect to time in the last 50 years. Multiple therapies are required by the type 2 diabetes patients r proper treatment of hyperglycaemic condition Linagliptin is the latest approved oral hypoglycaemic agent which act by inhibition of DPP-4 (Dipeptidyl peptidase-4) enzyme. On 2 May 2011, USFDA approved Linagliptin based on a large development program, including 4 trials on type 2 diabetes patients. In type 2 diabetes patients there is dysfuctioning of incretin hormones (Glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP). Inhibition of DPP-4 enzyme causes the slow down of inactivation of GLP-1 and GIP, which promotes the secretion of insulin. In present era, Linagliptin is the most potent oral hypoglycaemic agent which is indicated r the treatment of type 2 diabetes.